Becker's Healthcare November 1, 2024
U.S. pharmaceutical companies are seeking to lessen their reliance on China-based companies for drug production, ingredients and research, The Wall Street Journal reported Nov. 1.
Geopolitical conflicts, such as cargo ship attacks in the Red Sea and spy balloons above the U.S., have encouraged domestic medical supply companies to reduce their dependence on foreign businesses.
Quality issues have also driven nearshoring efforts; for example, in 2023, the FDA warned that some China-made syringes were breaking and leaking, prompting American companies to ramp up syringe production.
Attempts to shift away from Chinese pharmaceutical suppliers can be difficult, however, since China produces 32% of the world’s supply of antibiotics. One drugmaker in China, WuXi AppTec, is estimated...
Today's Sponsors
Today's Sponsor